Formulary
Deucravacitinib: Indications, Dosing, Side Effects and Interactions
Deucravacitinib selectively inhibits tyrosine kinase 2 (TYK2), which is a member of the Janus kinase (JAK) family; this inhibits the release of...
MedNext Academy | 3 min read
Deucravacitinib: Indications, Dosing, Side Effects and Interactions
Deucravacitinib selectively inhibits tyrosine kinase 2 (TYK2), which is a member of the Janus kinase (JAK) family; this inhibits the release of...
Drug action
Deucravacitinib selectively inhibits tyrosine kinase 2 (TYK2), which is a member of the Janus kinase (JAK) family; this inhibits the release of pro-inflammatory cytokines and chemokines.
Indications and dose
**Plaque psoriasis (initiated by a specialist)**
- **Adult** (By Mouth): 6 mg once daily, consider discontinuation of treatment if no response after 24 weeks.
Cautions
Chronic infection; elderly (75 years and older); history of recurrent infection Cautions, further information Tuberculosis Patients with latent tuberculosis should be started on anti-tuberculosis therapy before initiation of deucravacitinib. Consider anti-tuberculosis therapy before initiation of deucravacitinib in patients with a history of latent or active tuberculosis in whom an adequate course of treatment cannot be confirmed. M Immunisation Patients should receive all recommended vaccinations before initiating treatment; live vaccines are not recommended during treatment. M
Contraindications
Active infection
Side effects
Common or very common Increased risk of infection; oral disorders; skin reactions Frequency not known Malignancy; neoplasms
Interactions
**Other interactions (3):**
- Clinical studies indicate that deucravacitinib does not have clinically relevant drug interactions upon coadministration with the following other medicinal products and therefore no dose adjustments...
- Effect of deucravacitinib on other medicinal products Deucravacitinib does not meaningfully impact plasma exposures of rosuvastatin (BCRP and OATP substrate), methotrexate (substrate of BCRP and...
- Effect of other medicinal products on deucravacitinib Medicinal products that are inhibitors or inducers of CYP enzymes or transporters such as cyclosporine (dual P-gp/breast cancer resistance...
Pregnancy
Avoid (limited information available). M
Breast feeding
Avoid (present in milk in animal studies). M
Hepatic impairment
Avoid in severe impairment. M
Medicinal forms
Clinical governance
**Author:** MedNext Clinical Team. **Clinical reviewer:** Dr Shameer Deen, MBBS, MS, MRCS. **Sources:** BNF, Indian Pharmacopoeia, CIMS India. **Correction:** Report errors at support@mednext.academy.
Inside MedNext for this topic
- 411 MedNext-authored chapters
- 80,000+ MCQ bank
- 15 study modes
- Growing visual cheat sheets
Study modes
- Notes
- MCQ
- Audio
- Video
- Visual
- 3D Anatomy
- Trace
- Flashcards
- Mnemonics
- Image Bank
- Clinical
- Microscopy
- Audio QBank
- Cadaver
- Book Match
Continue reading
Subject HubPharmacology Hub
All pharmacology resources in one place.
Drug SchedulesIndian Drug Schedules
Schedule H, H1, X and G classifications.
FormularyBrowse all drugs
Search 1,850+ drug profiles.
Study Deucravacitinib in the MedNext app
Challenge yourself with targeted pharmacology MCQs on this drug class. Every explanation links back to the chapter that teaches the concept.
Start drug challengeExplore the full formulary

